Stuart H Ralston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3738462/publications.pdf

Version: 2024-02-01

174 papers

13,117 citations

23567 58 h-index 24982 109 g-index

186 all docs

186 docs citations

186 times ranked 15837 citing authors

#	Article	IF	CITATIONS
1	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	21.4	1,100
2	Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I $\hat{l}\pm 1$ gene. Nature Genetics, 1996, 14, 203-205.	21.4	639
3	Wholeâ€genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature, 2015, 526, 112-117.	27.8	483
4	Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genetics, 2000, 24, 45-48.	21.4	457
5	Nitric oxide and bone. Immunology, 2001, 103, 255-261.	4.4	444
6	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. JAMA Oncology, 2017, 3, 636.	7.1	376
7	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 2017, 105, 11-17.	2.9	373
8	Genetics of Osteoporosis. Endocrine Reviews, 2010, 31, 629-662.	20.1	316
9	Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Human Molecular Genetics, 2002, 11, 2735-2739.	2.9	307
10	Genetic regulation of bone mass and susceptibility to osteoporosis. Genes and Development, 2006, 20, 2492-2506.	5.9	275
11	Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nature Genetics, 2010, 42, 520-524.	21.4	258
12	Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. American Journal of Human Genetics, 2018, 102, 88-102.	6.2	252
13	Pathogenesis and management of Paget's disease of bone. Lancet, The, 2008, 372, 155-163.	13.7	227
14	Guidelines on the management of Paget's disease of bone*. Bone, 2002, 31, 366-373.	2.9	205
15	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2020, 396, 1745-1757.	13.7	192
16	Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro. Calcified Tissue International, 2008, 82, 191-201.	3.1	187
17	Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study. PLoS Medicine, 2006, 3, e90.	8.4	160
18	Nitric oxide and bone. Journal of Bone and Mineral Research, 1996, 11, 300-305.	2.8	158

#	Article	IF	CITATIONS
19	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nature Genetics, 2011, 43, 685-689.	21.4	158
20	An Sp1 Binding Site Polymorphism in the COLIA1 Gene Predicts Osteoporotic Fractures in Both Men and Women. Journal of Bone and Mineral Research, 1998, 13, 1384-1389.	2.8	156
21	Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 2009, 10, 139-147.	16.2	151
22	Expression of Nitric Oxide Synthase Isoforms in Bone and Bone Cell Cultures. Journal of Bone and Mineral Research, 1997, 12, 1108-1115.	2.8	148
23	Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone. Journal of Bone and Mineral Research, 2010, 25, 20-31.	2.8	147
24	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nature Communications, 2017, 8, 80.	12.8	147
25	Paget's Disease of Bone. New England Journal of Medicine, 2013, 368, 644-650.	27.0	146
26	Meta-Analysis of Genome-Wide Scans Provides Evidence for Sex- and Site-Specific Regulation of Bone Mass. Journal of Bone and Mineral Research, 2007, 22, 173-183.	2.8	144
27	A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation. Oncogene, 2000, 19, 4437-4440.	5.9	133
28	A Negative Search for a Paramyxoviral Etiology of Paget's Disease of Bone: Molecular, Immunological, and Ultrastructural Studies in U.K. Patients. Journal of Bone and Mineral Research, 2000, 15, 2315-2329.	2.8	132
29	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	3.6	132
30	Paget's Disease of Bone: Evidence for a Susceptibility Locus on Chromosome 18q and for Genetic Heterogeneity. Journal of Bone and Mineral Research, 1998, 13, 911-917.	2.8	125
31	Loci for regulation of bone mineral density in men and women identified by genome wide linkage scan: the FAMOS study. Human Molecular Genetics, 2005, 14, 943-951.	2.9	124
32	Pathogenesis of Paget Disease of Bone. Calcified Tissue International, 2012, 91, 97-113.	3.1	123
33	Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology, 2014, 53, 1759-1766.	1.9	119
34	Cerebrovascular Disease in Rheumatic Diseases. Stroke, 2016, 47, 943-950.	2.0	117
35	A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Human Molecular Genetics, 2011, 20, 2734-2744.	2.9	114
36	Genomewide Search in Familial Paget Disease of Bone Shows Evidence of Genetic Heterogeneity with Candidate Loci on Chromosomes 2q36, 10p13, and 5q35. American Journal of Human Genetics, 2001, 69, 1055-1061.	6.2	113

#	Article	IF	CITATIONS
37	Phenotypic Characterization of Early Onset Paget's Disease of Bone Caused by a 27-bp Duplication in the TNFRSF11A Gene. Journal of Bone and Mineral Research, 2003, 18, 1381-1385.	2.8	109
38	A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. Annals of the Rheumatic Diseases, 2014, 73, 2130-2136.	0.9	108
39	Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. Journal of Bone and Mineral Research, 2019, 34, 579-604.	2.8	102
40	Loss of Ubiquitin-Binding Associated With Paget's Disease of Bone p62 (SQSTM1) Mutations. Journal of Bone and Mineral Research, 2004, 20, 619-624.	2.8	97
41	Pathogenesis of Paget's disease of bone. Bone, 2008, 43, 819-825.	2.9	95
42	The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation. Endocrinology, 2011, 152, 2141-2149.	2.8	92
43	Clinical Presentation of Paget's Disease: Evaluation of a Contemporary Cohort and Systematic Review. Calcified Tissue International, 2014, 95, 385-392.	3.1	89
44	The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas!. Rheumatology, 1997, 36, 831-838.	1.9	88
45	Failure to detect paramyxovirus sequences in paget's disease of bone using the polymerase chain reaction. Journal of Bone and Mineral Research, 1991, 6, 1243-1248.	2.8	81
46	Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bon. Journal of Bone and Mineral Research, 1994, 9, 11-16.	2.8	77
47	Mutations of <i>SQSTM1</i> are associated with severity and clinical outcome in paget disease of bone. Journal of Bone and Mineral Research, 2010, 25, 2368-2373.	2.8	77
48	Mutation Screening of the TNFRSF11A Gene Encoding Receptor Activator of NFkB (RANK) in Familial and Sporadic Paget's Disease of Bone and Osteosarcoma. Calcified Tissue International, 2001, 68, 151-155.	3.1	75
49	Genetics of osteoporosis. Annals of the New York Academy of Sciences, 2010, 1192, 181-189.	3.8	75
50	TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. Journal of Clinical Investigation, 2018, 128, 1164-1177.	8.2	75
51	SIDE-EFFECTS OF PAMIDRONATE. Lancet, The, 1989, 334, 42-43.	13.7	74
52	The Influence of Vitamin C on the Outcome of Distal Radial Fractures. Journal of Bone and Joint Surgery - Series A, 2014, 96, 1451-1459.	3.0	72
53	Genetic determinants of osteoporosis. Current Opinion in Rheumatology, 2005, 17, 475-479.	4.3	70
54	Genetics of osteoporosis. Proceedings of the Nutrition Society, 2007, 66, 158-165.	1.0	70

#	Article	IF	CITATIONS
55	COL1A1 Sp1 Polymorphism Predicts Perimenopausal and Early Postmenopausal Spinal Bone Loss. Journal of Bone and Mineral Research, 2001, 16, 1634-1641.	2.8	66
56	COLIA1 Sp1 Polymorphism Predicts Response of Femoral Neck Bone Density to Cyclical Etidronate Therapy. Calcified Tissue International, 2002, 70, 158-163.	3.1	65
57	Multicenter Blinded Analysis of RT-PCR Detection Methods for Paramyxoviruses in Relation to Paget's Disease of Bone. Journal of Bone and Mineral Research, 2007, 22, 569-577.	2.8	65
58	The genetics of osteoporosis. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 247-251.	0.5	64
59	Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget's Disease. Cell Reports, 2015, 13, 1096-1102.	6.4	61
60	Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial. Circulation, 2021, 143, 2418-2427.	1.6	61
61	Susceptibility to Paget's Disease of Bone Is Influenced by a Common Polymorphic Variant of Osteoprotegerin. Journal of Bone and Mineral Research, 2004, 19, 1506-1511.	2.8	59
62	Identification of Sex-Specific Associations Between Polymorphisms of the Osteoprotegerin Gene, TNFRSF11B, and Paget's Disease of Bone. Journal of Bone and Mineral Research, 2007, 22, 1062-1071.	2.8	59
63	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 2017, 38, ehw387.	2.2	58
64	Association of COLIA1 Sp1 Alleles with Defective Bone Nodule Formation In Vitro and Abnormal Bone Mineralization In Vivo. Calcified Tissue International, 2005, 77, 113-118.	3.1	57
65	Heavy Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of Fractures. American Journal of Medicine, 2017, 130, 214-221.	1.5	56
66	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1682-1699.	3.6	53
67	Common susceptibility alleles and <i>SQSTM1</i> mutations predict disease extent and severity in a multinational study of patients with Paget's disease. Journal of Bone and Mineral Research, 2013, 28, 2338-2346.	2.8	50
68	Cerebral Small Vessel Disease Burden Is Increased in Systemic Lupus Erythematosus. Stroke, 2016, 47, 2722-2728.	2.0	50
69	Longâ€Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISMâ€EZ Study. Journal of Bone and Mineral Research, 2017, 32, 1165-1173.	2.8	50
70	Biology and Treatment of Paget's Disease of Bone. Journal of Cellular Biochemistry, 2016, 117, 289-299.	2.6	49
71	Management of Osteogenesis Imperfecta. Frontiers in Endocrinology, 2019, 10, 924.	3.5	49
72	Identification of a Major Locus for Paget's Disease on Chromosome 10p13 in Families of British Descent. Journal of Bone and Mineral Research, 2008, 23, 58-63.	2.8	47

#	Article	IF	CITATIONS
73	The Effect of Nutrient Intake on Bone Mineral Status in Young Adults: The Northern Ireland Young Hearts Project. Calcified Tissue International, 2002, 70, 89-98.	3.1	43
74	Clinical Guidelines on Paget's Disease of Bone. Journal of Bone and Mineral Research, 2019, 34, 2327-2329.	2.8	43
75	Genetic variation in the <i>TNFRSF11A</i> gene encoding RANK is associated with susceptibility to Paget's disease of bone. Journal of Bone and Mineral Research, 2010, 25, 2592-2605.	2.8	42
76	Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 2014, 44, 25-30.	3.4	42
77	Novel Genetic Variants Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of <i>SLC1A3</i> and <i>EPHB2</i> Journal of Bone and Mineral Research, 2016, 31, 2085-2097.	2.8	42
78	The Pro and Con of Measles Virus in Paget's Disease: Con. Journal of Bone and Mineral Research, 2002, 17, 2290-2292.	2.8	40
79	The synthesis and evaluation of o-phenylenediamine derivatives as fluorescent probes for nitric oxide detection. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 2553-2559.	1.3	39
80	Combined deficiency of the Cnr1 and Cnr2 receptors protects against ageâ€related bone loss by osteoclast inhibition. Aging Cell, 2017, 16, 1051-1061.	6.7	39
81	Genetic determinants of susceptibility to osteoporosis. Current Opinion in Pharmacology, 2003, 3, 286-290.	3.5	38
82	Disentangling the genetics of lean mass. American Journal of Clinical Nutrition, 2019, 109, 276-287.	4.7	38
83	Genetics of Paget's Disease of Bone. Current Osteoporosis Reports, 2014, 12, 263-271.	3.6	37
84	Clinical experience with pamidronate in the treatment of Paget's disease of bone Annals of the Rheumatic Diseases, 1991, 50, 930-933.	0.9	36
85	Studies of Bone Density, Quantitative Ultrasound, and Vertebral Fractures in Relation to Collagen Type I Alpha 1 Alleles in Elderly Women. Calcified Tissue International, 2001, 68, 348-351.	3.1	36
86	Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders. Best Practice and Research in Clinical Rheumatology, 2008, 22, 101-111.	3.3	36
87	Hydrogen sulphideâ€releasing diclofenac derivatives inhibit breast cancerâ€induced osteoclastogenesis <i>in vitro</i> and prevent osteolysis <i>ex vivo</i> British Journal of Pharmacology, 2012, 165, 1914-1925.	5.4	34
88	Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. Journal of Biological Chemistry, 2015, 290, 22049-22060.	3.4	33
89	Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget's disease of bone. Biochemical Society Transactions, 2004, 32, 728-730.	3.4	32
90	The effect of 1α-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated paget's disease â€" a double-blind randomized clinical study. Journal of Bone and Mineral Research, 1987, 2, 5-12.	2.8	32

#	Article	IF	Citations
91	Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance. Calcified Tissue International, 2021, 109, 351-362.	3.1	32
92	Role of genetic factors in the pathophysiology and management of osteoporosis. Clinical Endocrinology, 2001, 54, 1-9.	2.4	31
93	Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 2019, 44, 452-466.	6.1	30
94	Targeted sequencing of the Paget's disease associated 14q32 locus identifies several missense coding variants in RIN3 that predispose to Paget's disease of bone. Human Molecular Genetics, 2015, 24, 3286-3295.	2.9	29
95	Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus, 2017, 26, 588-597.	1.6	29
96	Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 992-1000.	3.8	28
97	Randomized Trial of Alendronate Plus Vitamin D3 Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency. Calcified Tissue International, 2011, 88, 485-494.	3.1	27
98	Signal peptide mutations in RANK prevent downstream activation of NF-κB. Journal of Bone and Mineral Research, 2011, 26, 1926-1938.	2.8	27
99	Raman spectroscopy predicts the link between claw keratin and bone collagen structure in a rodent model of oestrogen deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 398-406.	3.8	26
100	Rare Inherited forms of Paget's Disease and Related Syndromes. Calcified Tissue International, 2019, 104, 501-516.	3.1	26
101	p62 mutations, ubiquitin recognition and Paget's disease of bone. Biochemical Society Transactions, 2006, 34, 735-737.	3.4	25
102	Genetic determinants of Paget's disease of bone. Annals of the New York Academy of Sciences, 2011, 1240, 53-60.	3.8	25
103	Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcified Tissue International, 2017, 101, 375-383.	3.1	25
104	Pharmacological Management of Back Pain Syndromes. Drugs, 1994, 48, 189-198.	10.9	24
105	Medical Management of Hypercalcemia. Calcified Tissue International, 2003, 74, 1-11.	3.1	23
106	Lossâ€ofâ€Function Mutations in the <i>ALPL</i> Gene Presenting with Adult Onset Osteoporosis and Low Serum Concentrations of Total Alkaline Phosphatase. Journal of Bone and Mineral Research, 2020, 35, 657-661.	2.8	23
107	Pathogenesis and management of cancer associated hypercalcaemia. Cancer Surveys, 1994, 21, 179-96.	1.5	23
108	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 2016, 17, 461.	1.9	22

#	Article	IF	CITATIONS
109	Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2019, 34, 1025-1032.	2.8	22
110	Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis. Calcified Tissue International, 2022, 110, 273-284.	3.1	22
111	Paget's disease of bone. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 865-869.	0.5	21
112	Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover. Calcified Tissue International, 2014, 94, 259-268.	3.1	21
113	Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. Annals of the Rheumatic Diseases, 2018, 77, 378-385.	0.9	21
114	Antibody Response to Paramyxoviruses in Paget's Disease of Bone. Calcified Tissue International, 2017, 101, 141-147.	3.1	20
115	Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 2022, 17, 23.	2.7	19
116	Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review. Acta Ophthalmologica, 2022, 100, .	1.1	18
117	Do genetic markers aid in risk assessment?. Osteoporosis International, 1998, 8 Suppl 1, S37-42.	3.1	18
118	Bisphosphonates in the management of Paget's disease. Bone, 2020, 138, 115465.	2.9	17
119	The effect of hyperoxia on the expression of cytokine mRNA in endothelial cells. Biochemical Society Transactions, 1997, 25, 292S-292S.	3.4	16
120	Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1631-1632.	0.9	16
121	Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to preventSQSTM1-mediated Paget's disease of bone. BMJ Open, 2019, 9, e030689.	1.9	15
122	Osteoporosis as an Hereditary Disease. Clinical Reviews in Bone and Mineral Metabolism, 2010, 8, 68-76.	0.8	14
123	Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice. Annals of the Rheumatic Diseases, 2015, 74, 220-226.	0.9	14
124	Cognitive function, disease burden and the structural connectome in systemic lupus erythematosus. Lupus, 2018, 27, 1329-1337.	1.6	14
125	Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate. Calcified Tissue International, 2010, 87, 298-304.	3.1	13
126	Characteristics of Early Paget's Disease in <scp><i>SQSTM1</i></scp> Mutation Carriers: Baseline Analysis of the <scp>ZiPP</scp> Study Cohort. Journal of Bone and Mineral Research, 2020, 35, 1246-1252.	2.8	12

#	Article	IF	CITATIONS
127	Genetic Determinants of Paget's Disease of Bone. Current Osteoporosis Reports, 2021, 19, 327-337.	3.6	12
128	Raman spectral variation for human fingernails of postmenopausal women is dependent on fracture risk and osteoporosis status. Journal of Raman Spectroscopy, 2017, 48, 813-821.	2.5	11
129	Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease. DMM Disease Models and Mechanisms, 2018, 11 , .	2.4	11
130	Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis. Calcified Tissue International, 2019, 105, 148-155.	3.1	11
131	Genetics of osteoporosis. , 2001, 2, 13-21.		10
132	Clinical and Biochemical Response of TNFRSF11A-Mediated Early-Onset Familial Paget Disease to Bisphosphonate Therapy. Calcified Tissue International, 2008, 83, 272-275.	3.1	10
133	Raman Spectroscopic Analysis of Fingernail Clippings Can Help Differentiate between Postmenopausal Women who Have and Have Not Suffered a Fracture. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2016, 9, CMAMD.S38493.	1.2	10
134	Osteoimmunology. Calcified Tissue International, 2018, 102, 501-502.	3.1	10
135	Insertion Mutation in Tnfrsf11a Causes a Paget's Disease–Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice. Journal of Bone and Mineral Research, 2020, 36, 1376-1386.	2.8	10
136	Predictors of poor clinical outcome following hip fracture in middle aged-patients. Injury, 2015, 46, 709-712.	1.7	9
137	High mortality in younger patients with major osteoporotic fractures. Osteoporosis International, 2017, 28, 1047-1052.	3.1	9
138	Epigenetic analysis of Paget's disease of bone identifies differentially methylated loci that predict disease status. ELife, 2021, 10, .	6.0	9
139	Patient-Reported Outcomes in Rheumatoid Arthritis. Patient, 2010, 3, 133-143.	2.7	8
140	A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatology International, 2021, 41, 921-928.	3.0	8
141	Pathogenesis of Paget's Disease of Bone. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 109-114.	0.8	7
142	Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation. Calcified Tissue International, 2021, 109, 92-102.	3.1	7
143	Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis. Journal of Materials Science: Materials in Medicine, 2019, 30, 25.	3.6	6
144	Brain network reorganisation and spatial lesion distribution in systemic lupus erythematosus. Lupus, 2021, 30, 285-298.	1.6	6

#	Article	IF	Citations
145	Regulation of breast cancer induced bone disease by cancer-specific IKK \hat{I}^2 . Oncotarget, 2018, 9, 16134-16148.	1.8	6
146	Communicating Absolute Fracture Risk Reduction and the Acceptance of Treatment for Osteoporosis. Calcified Tissue International, 2022, 110, 698-702.	3.1	6
147	The Paget's disease of bone risk gene <i>PML</i> is a negative regulator of osteoclast differentiation and bone resorption. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	6
148	Genetic markers of bone metabolism and bone disease. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 114-121.	1.2	5
149	Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020. Frontiers in Endocrinology, 2020, 11, 630875.	3.5	5
150	Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro. Calcified Tissue International, 2021, 109, 696-705.	3.1	5
151	Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence Based. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L45-L46.	3 . 6	5
152	Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 2022, 17, 12.	2.4	5
153	A New Gene for Susceptibility to Paget's Disease of Bone and for Multisystem Proteinopathy. Journal of Bone and Mineral Research, 2020, 35, 1385-1386.	2.8	4
154	Ubiquitin-protein ligase Ubr5 cooperates with hedgehog signalling to promote skeletal tissue homeostasis. PLoS Genetics, 2021, 17, e1009275.	3.5	4
155	Liver-derived IGF-I is not required for protection against osteoarthritis in male mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1150-E1157.	3. 5	3
156	Adult hypophosphatasia with a novel ALPL mutation: Report of an Indian kindred. Bone Reports, 2020, 12, 100247.	0.4	3
157	Genetic markers of bone metabolism and bone disease. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement, 1997, 227, 114-21.	2.7	3
158	Epigenetic DNA Methylation Signatures Associated With the Severity of Paget's Disease of Bone. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	3
159	Apolipoprotein E isoforms and bone—of mice and men. Journal of Bone and Mineral Research, 2013, 28, 234-235.	2.8	2
160	Paget's disease of bone: when and why to refer to specialist care. British Journal of General Practice, 2020, 70, 561-562.	1.4	2
161	Pattern of SQSTM1 Gene Variants in a Hungarian Cohort of Paget's Disease of Bone. Calcified Tissue International, 2021, 108, 159-164.	3.1	2
162	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. Scandinavian Journal of Rheumatology, 2022, , 1-6.	1.1	2

#	Article	IF	CITATIONS
163	New Targets and New Treatments: Recent Advances in the Treatment of Musculoskeletal Disease. Calcified Tissue International, 2016, 98, 317-318.	3.1	1
164	How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders. Journal of Bone and Mineral Research, 2017, 32, 2324-2330.	2.8	1
165	Rheumatology in a time of Coronavirus: lessons from our early experiences. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 715-716.	0.5	1
166	Mind the gaps: therapists' experiences of managing symptomatic hypermobility in Scotland. Rheumatology Advances in Practice, 2021, 5, rkab046.	0.7	1
167	$200 \hat{a} \in f$ Autoantibodies to Osteoprotegerin and Bone Mineral Density in Axial Spondyloarthritis. Rheumatology, $2016, \ldots$	1.9	0
168	The Reply. American Journal of Medicine, 2017, 130, e457.	1.5	0
169	Focal and Osteosclerotic Bone Diseases. Calcified Tissue International, 2019, 104, 481-482.	3.1	0
170	Analysis of Transcriptional Regulation in Bone Cells. Methods in Molecular Biology, 2019, 1914, 145-167.	0.9	0
171	Response to: Effects of Alendronic Acid on Fracture Healing. Journal of Bone and Mineral Research, 2020, 35, 215-216.	2.8	0
172	$P112\hat{a} \in f$ Teriparatide versus anti-resorptive treatment in rheumatoid arthritis patients with severe osteoporosis: an observational study. Rheumatology, 2021, 60, .	1.9	0
173	Response by Bing et al to Letter Regarding Article, "Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial― Circulation, 2021, 144, e335.	1.6	0
174	Unusual Causes of Osteoporosis. Calcified Tissue International, 2022, 110, 529-530.	3.1	0